Department of Radiation Oncology, Changzhou Tumor Hospital Soochow University, Changzhou 213002, Jiangsu Province, China.
J Gastrointest Surg. 2013 Jul;17(7):1181-7. doi: 10.1007/s11605-013-2204-7. Epub 2013 Apr 23.
Small cell carcinoma of esophagus (SCEC) is characterized by high malignancy and early metastasis. Although the morbidity of SCEC is very low, few studies of patients with SCEC have been conducted in China, there are no sufficient studies of SCEC conducted and reported in the existing published works, and the choices of treatment remain controversial. In this work, we aim to study the clinical characteristics of SCEC, and explore the corresponding treatment and prognosis through retrospective analysis.
The original articles were identified through the leading digital libraries in China in which the terms "esophagus or esophageal" and "small cell esophageal carcinoma" appeared from 2005 to 2009, 1,176 eligible cases were reviewed for clinical data. Analysis of survival was conducted using the Kaplan-Meier method, and differences were compared using the log-rank test.
One thousand one hundred seventy-six eligible cases were analyzed; the median age of patients was 57 years, with a male-to-female ratio of 2.4:1. The number of SCEC accounted for 1.26 % of esophageal cancer treated in the same period. Of the tumors, 89.7 % were located in mid- and lower thoracic esophagus. The average tumor length was 5.4 cm (0.5-17 cm). The median overall survival was 11.1 months for all patients. The 1-, 2-, 3-, and 5-year average overall survival rates of 469 patients was 51.1, 25.5, 13.2, 7.9 %, respectively. The median survival time for LD patients who received systemic treatment was 16.8 m, whereas for those who received local treatment (surgery), the median survival time was 10.1 m; the median survival time for ED patients who received systemic treatment was 7.4 m, compared with 5.8 m for those who received sole treatment (chemotherapy or radiotherapy).
SCEC is a tumor characterized by high malignancy and early metastasis. Although our retrospective analysis cannot provide definitive conclusions on the optimal treatment modality for SCEC, however, our results suggest that systemic treatment combined with surgical resection plays a major role in the therapy of SCEC, systemic therapy may be an effective approach for the treatment of SCEC, and randomized, prospective, multicenter studies are needed to identify optimal treatment modalities for SCEC.
食管小细胞癌(SCEC)的特点是恶性程度高,转移早。虽然 SCEC 的发病率非常低,但中国对 SCEC 患者的研究很少,现有文献中也没有足够的 SCEC 研究报道,治疗选择仍存在争议。本研究旨在通过回顾性分析,研究 SCEC 的临床特征,并探讨相应的治疗和预后。
通过中国主要数字图书馆检索 2005 年至 2009 年间出现“食管或食管”和“食管小细胞癌”的原始文章,共回顾了 1176 例符合条件的病例进行临床数据分析。采用 Kaplan-Meier 法进行生存分析,采用对数秩检验比较差异。
分析了 1176 例符合条件的病例;患者的中位年龄为 57 岁,男女比例为 2.4:1。SCEC 数量占同期食管癌治疗的 1.26%。肿瘤中,89.7%位于中下段食管。平均肿瘤长度为 5.4cm(0.5-17cm)。所有患者的中位总生存期为 11.1 个月。469 例患者的 1、2、3、5 年总生存率分别为 51.1%、25.5%、13.2%、7.9%。接受全身治疗的 LD 患者的中位生存时间为 16.8m,而接受局部治疗(手术)的患者中位生存时间为 10.1m;接受全身治疗的 ED 患者的中位生存时间为 7.4m,而仅接受化疗或放疗的患者的中位生存时间为 5.8m。
SCEC 是一种恶性程度高、转移早的肿瘤。虽然我们的回顾性分析不能为 SCEC 的最佳治疗方式提供明确的结论,但我们的结果表明,全身治疗联合手术切除在 SCEC 的治疗中起主要作用,全身治疗可能是治疗 SCEC 的有效方法,需要进行随机、前瞻性、多中心研究以确定 SCEC 的最佳治疗方式。